About
News, Events & Presentations
Press Releases | Events Calendar | Presentations

Keyword Search
 
2019 | 2018 | 2017 | 2016
DateTitle 
05/30/19Fibrocell to Present at BIO International Convention 2019Printer Friendly Version
05/29/19Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEBPrinter Friendly Version
05/15/19Fibrocell Reports First Quarter 2019 Financial Results and Recent Operational HighlightsPrinter Friendly Version
05/09/19Fibrocell to Host Conference Call and Webcast on Wednesday, May 15, 2019 to Discuss First Quarter 2019 Financial Results and Recent Operational HighlightsPrinter Friendly Version
04/15/19Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene TherapyPrinter Friendly Version
04/03/19Fibrocell Announces Board Member Christine St.Clare Honored by National Association of Corporate DirectorsPrinter Friendly Version
03/27/19Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007Printer Friendly Version
03/20/19Fibrocell to Host Conference Call & Webcast for Full Year 2018 Financial Results and Recent Highlights on March 27, 2019Printer Friendly Version
02/06/19Fibrocell to Present at 21st Annual BIO CEO & Investor ConferencePrinter Friendly Version
01/16/19Fibrocell to Present at Phacilitate Leaders World 2019Printer Friendly Version
12/11/18Fibrocell Receives $900,000 Investment from EB Research Partnership and Epidermolysis Bullosa Medical Research FoundationPrinter Friendly Version
11/13/18Fibrocell Reports Third Quarter 2018 Financial Results and Recent HighlightsPrinter Friendly Version
11/08/18Fibrocell to Host Conference Call and Webcast on Tuesday, November 13, 2018 to Discuss Third Quarter 2018 Financial Results and Recent HighlightsPrinter Friendly Version
10/25/18Fibrocell Receives Guidance from FDA on Phase 3 Clinical Trial Design for FCX-007Printer Friendly Version
09/26/18Fibrocell to Present at Upcoming Industry and Investor ConferencesPrinter Friendly Version
09/25/18Fibrocell Awarded $1.4 Million FDA Orphan Grant for FCX-007 for Treatment of Recessive Dystrophic Epidermolysis BullosaPrinter Friendly Version
09/05/18Fibrocell Announces FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized SclerodermaPrinter Friendly Version
08/29/18Fibrocell to Present at 20th Annual Rodman & Renshaw Global Investment ConferencePrinter Friendly Version
08/09/18Fibrocell Reports Second Quarter 2018 Financial Results and Recent HighlightsPrinter Friendly Version
08/02/18Fibrocell to Host Conference Call and Webcast on Thursday, August 9, 2018 to Discuss Second Quarter 2018 Financial Results and Recent HighlightsPrinter Friendly Version
07/05/18Fibrocell Announces Closing of $4.0 Million Registered Direct OfferingPrinter Friendly Version
07/02/18Fibrocell Announces $4.0 Million Registered Direct Offering Priced At-the-MarketPrinter Friendly Version
05/31/18Fibrocell Announces Closing of $6.0 Million Registered Direct OfferingPrinter Friendly Version
05/29/18Fibrocell Announces $6.0 Million Registered Direct Offering Priced At-the-MarketPrinter Friendly Version
05/24/18Fibrocell Announces One-for-Five Reverse Stock SplitPrinter Friendly Version
05/21/18Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis BullosaPrinter Friendly Version
05/16/18Fibrocell Announces Oral Presentation at 7th International Investigative Dermatology MeetingPrinter Friendly Version
05/10/18Fibrocell Reports First Quarter 2018 Financial Results and Recent HighlightsPrinter Friendly Version
05/03/18Fibrocell to Host Conference Call and Webcast on Thursday, May 10, 2018 to Discuss First Quarter 2018 Financial Results and Recent HighlightsPrinter Friendly Version
04/18/18Fibrocell Announces Review of Strategic AlternativesPrinter Friendly Version
04/10/18Fibrocell to Present at 6th Annual Cell & Gene Therapy Investor Day and 2018 World Orphan Drug Congress USAPrinter Friendly Version
03/19/18Fibrocell Reports 2017 Financial Results and Recent HighlightsPrinter Friendly Version
03/12/18Fibrocell to Host Conference Call and Webcast on Monday, March 19, 2018 to Discuss 2017 Financial Results and Recent HighlightsPrinter Friendly Version
03/06/18Fibrocell Announces FDA Allowance of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized SclerodermaPrinter Friendly Version
02/06/18Fibrocell to Present at 20th Annual BIO CEO & Investor ConferencePrinter Friendly Version
02/05/18Fibrocell Announces Submission of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized SclerodermaPrinter Friendly Version
01/30/18Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)Printer Friendly Version
01/24/18Fibrocell to Present at Phacilitate Cell and Gene Therapy World 2018 Printer Friendly Version
12/11/17Fibrocell Announces Closing of $10.5 Million Underwritten Public OfferingPrinter Friendly Version
12/07/17Fibrocell Announces Pricing of $10.5 Million Underwritten Public OfferingPrinter Friendly Version
11/13/17Fibrocell Reports Third Quarter 2017 Financial Results and Recent HighlightsPrinter Friendly Version
11/06/17Fibrocell to Host Conference Call and Webcast on Monday, November 13, 2017 to Discuss Third Quarter 2017 Financial Results and Recent Operational HighlightsPrinter Friendly Version
10/02/17Fibrocell to Present at 2017 Cell & Gene Meeting on the MesaPrinter Friendly Version
09/26/17Fibrocell Reports Interim Results of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis BullosaPrinter Friendly Version
09/05/17Fibrocell to Present at Rodman & Renshaw 19th Annual Global Investment Conference and Global Genes’ 2017 RARE Patient Advocacy SummitPrinter Friendly Version
08/09/17Fibrocell Reports Second Quarter 2017 Financial Results and Recent HighlightsPrinter Friendly Version
08/03/17Fibrocell to Present at Canaccord Genuity 37th Annual Growth ConferencePrinter Friendly Version
08/02/17Fibrocell to Host Conference Call and Webcast on Wednesday, August 9, 2017 to Discuss Second Quarter 2017 Financial Results and Recent Operational HighlightsPrinter Friendly Version
06/12/17Fibrocell Receives Rare Pediatric Disease Designation from FDA for FCX-013 for Treatment of Localized SclerodermaPrinter Friendly Version
06/08/17Fibrocell Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis BullosaPrinter Friendly Version
05/17/17Fibrocell to Present at Inaugural Cell & Gene Exchange 2017Printer Friendly Version
05/10/17Fibrocell Reports First Quarter 2017 Financial Results and Recent Operational HighlightsPrinter Friendly Version
05/09/17Fibrocell and Intrexon Announce Two Oral Presentations at the 20th Annual Meeting of the American Society of Gene & Cell TherapyPrinter Friendly Version
05/08/17Fibrocell Announces Data Safety Monitoring Board Recommends Continuation of Phase 1/2 Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis BullosaPrinter Friendly Version
05/03/17Fibrocell to Host Conference Call and Webcast on Wednesday, May 10, 2017 to Discuss First Quarter 2017 Financial Results and Recent Operational HighlightsPrinter Friendly Version
04/13/17Fibrocell to Present at 7th Annual World Orphan Drug Congress USA 2017 and 5th Annual Cell & Gene Therapy Investor DayPrinter Friendly Version
03/28/17Fibrocell Regains Compliance with NASDAQ Listing RequirementsPrinter Friendly Version
03/10/17Fibrocell Announces One-for-Three Reverse Stock SplitPrinter Friendly Version
03/09/17Fibrocell Reports 2016 Financial Results and Recent Operational HighlightsPrinter Friendly Version
03/07/17Fibrocell to Host Conference Call and Webcast on Thursday, March 9, 2017 to Discuss 2016 Financial Results and Recent Operational HighlightsPrinter Friendly Version
03/07/17Fibrocell Announces Convertible Preferred Stock Financing for $8.0 MillionPrinter Friendly Version
02/23/17Fibrocell Announces Dosing of First Patient in Phase I/II Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis BullosaPrinter Friendly Version
01/05/17Fibrocell Announces FDA Fast Track Designation of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis BullosaPrinter Friendly Version
12/19/16Fibrocell Announces Leadership ChangesPrinter Friendly Version
11/10/16Fibrocell Appoints Alfred T. Lane, MD, Chief Medical AdvisorPrinter Friendly Version
11/03/16Fibrocell Reports Third Quarter 2016 Financial Results and Recent Operational HighlightsPrinter Friendly Version
10/31/16Fibrocell to Host Conference Call and Webcast on Thursday, November 3, 2016 to Discuss Third Quarter 2016 Financial Results and Recent Operational HighlightsPrinter Friendly Version
09/29/16Fibrocell to Present at 2016 Cell & Gene Meeting on the MesaPrinter Friendly Version
09/19/16Fibrocell Completes Enrollment in NC1+ Cohort of Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis BullosaPrinter Friendly Version
09/08/16Fibrocell Announces Closing of $18 Million Private PlacementPrinter Friendly Version
08/09/16Fibrocell Announces Convertible Debt and Warrant Financing of Up to $25 MillionPrinter Friendly Version
08/08/16Fibrocell Announces Proposed Public Offering of Common Stock and WarrantsPrinter Friendly Version
08/04/16Fibrocell Reports Second Quarter 2016 Financial Results and Recent Operational HighlightsPrinter Friendly Version
07/28/16Fibrocell to Host Conference Call and Webcast on Thursday, August 4, 2016 to Discuss Second Quarter 2016 Financial Results and Recent Operational HighlightsPrinter Friendly Version
07/27/16Fibrocell Announces First Subjects Enrolled in Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis BullosaPrinter Friendly Version
07/07/16Fibrocell to Present at Cantor Fitzgerald’s 2nd Annual Healthcare ConferencePrinter Friendly Version
06/29/16Fibrocell Expects Significant Cost Savings from Wind-Down of azficel-T OperationsPrinter Friendly Version
06/13/16Fibrocell Announces Initiation of Patient Recruitment in Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis BullosaPrinter Friendly Version
06/08/16Fibrocell Reports Phase II azficel-T Trial for Treatment of Vocal Cord Scarring Did Not Meet Primary EndpointsPrinter Friendly Version
05/05/16Fibrocell Reports First Quarter 2016 Financial Results and Operational HighlightsPrinter Friendly Version
04/28/16Fibrocell to Host Conference Call and Webcast on Thursday, May 5, 2016 to Discuss First Quarter 2016 Financial Results and Recent Operational HighlightsPrinter Friendly Version
04/25/16Fibrocell Receives Orphan Drug Designation from the FDA for FCX-013 for the Treatment of Localized SclerodermaPrinter Friendly Version
04/21/16Fibrocell Announces Last Patient Visit for Primary Endpoint Analysis in Phase II Clinical Trial of azficel-T for the Treatment of Vocal Cord ScarringPrinter Friendly Version
04/18/16Fibrocell and Intrexon Announce Allowance to Commence Phase I/II Trial for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)Printer Friendly Version
03/15/16Fibrocell to Present at the Alliance for Regenerative Medicine’s 4th Annual Cell & Gene Therapy Investor DayPrinter Friendly Version
03/10/16Fibrocell Reports Fourth Quarter and Full Year 2015 Financial Results and Operational HighlightsPrinter Friendly Version
03/08/16Fibrocell to Present at 28th Annual ROTH ConferencePrinter Friendly Version
03/03/16Fibrocell to Report Fourth Quarter and Full Year 2015 Financial Results and Operational Highlights, and Host Conference Call and Webcast on Thursday, March 10, 2016Printer Friendly Version
02/16/16Fibrocell to Present at RBC Capital Markets 2016 Global Healthcare ConferencePrinter Friendly Version
01/27/16Fibrocell Highlights Recent Pipeline AccomplishmentsPrinter Friendly Version
01/04/16Fibrocell and Intrexon Announce Collaboration to Address Chronic Inflammatory and Degenerative Diseases of the JointPrinter Friendly Version
11/05/15Fibrocell Science Reports Third Quarter 2015 Financial Results and Operational HighlightsPrinter Friendly Version
10/29/15Fibrocell to Report Third Quarter 2015 Financial and Operating Results, and Host Conference Call and Webcast on Thursday, November 5, 2015Printer Friendly Version
10/08/15Fibrocell and Intrexon Announce Poster Presentation on FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) at American Society of Human Genetics Annual MeetingPrinter Friendly Version
10/01/15Fibrocell to Present at 2015 Stem Cell Meeting on the MesaPrinter Friendly Version
09/25/15Fibrocell and Intrexon Provide Regulatory Update for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)Printer Friendly Version
09/03/15Fibrocell to Present at Multiple Investor Conferences in SeptemberPrinter Friendly Version
08/06/15Fibrocell Science Reports Second Quarter 2015 Financial Results and Operational HighlightsPrinter Friendly Version
08/04/15Fibrocell to Present at 2015 Wedbush PacGrow Healthcare ConferencePrinter Friendly Version
07/30/15Fibrocell to Report Second Quarter 2015 Financial and Operating Results, and Host Conference Call and Webcast on Thursday, August 6, 2015Printer Friendly Version
07/22/15Fibrocell Announces Pricing of Public Offering of Common StockPrinter Friendly Version
07/21/15Fibrocell Announces Proposed Public Offering of Common StockPrinter Friendly Version
07/20/15Fibrocell and Intrexon Announce IND Filing of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)Printer Friendly Version
06/29/15Fibrocell Joins the Russell 2000(R) IndexPrinter Friendly Version
06/08/15Fibrocell and Intrexon Announce Positive in vitro Pre-Clinical Data for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) at European Society of Human GeneticsPrinter Friendly Version
06/01/15Fibrocell Appoints Michael F. Marino as Senior Vice President, General Counsel and Corporate SecretaryPrinter Friendly Version
05/28/15Fibrocell and Intrexon Announce Poster Presentation on FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB) at the European Society of Human Genetics Annual Meeting 2015Printer Friendly Version
05/26/15Fibrocell to Present at Jefferies 2015 Global Healthcare ConferencePrinter Friendly Version
05/12/15Fibrocell Receives Rare Pediatric Disease Designation From FDA for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)Printer Friendly Version
05/08/15Fibrocell Science Reports First Quarter 2015 Financial and Operating ResultsPrinter Friendly Version
05/01/15Fibrocell Science to Report First Quarter 2015 Financial and Operating Results, and Host Conference Call and Webcast on Friday, May 8, 2015Printer Friendly Version
04/17/15Fibrocell Science to Present at World Orphan Drug Congress USA 2015Printer Friendly Version
03/18/15Fibrocell Science Appoints Keith A. Goldan, Senior Vice President and Chief Financial OfficerPrinter Friendly Version
03/13/15Fibrocell Science Reports Fourth Quarter and Full Year 2014 Financial and Operating ResultsPrinter Friendly Version
03/05/15Fibrocell Science to Report Fourth Quarter 2014 and Full Year 2014 Financial and Operating Results, and Host Conference Call and Webcast on March 13, 2015Printer Friendly Version
01/07/15Fibrocell Science to Present at Biotech Showcase 2015 ConferencePrinter Friendly Version
11/18/14Fibrocell Science Announces IND Allowed to Proceed to Develop New Treatment for Wounded Warrior Amputees to Prevent Stump Skin DiseasesPrinter Friendly Version
11/07/14Fibrocell Science Reports Third Quarter and Nine Month 2014 Financial and Operating ResultsPrinter Friendly Version
10/30/14Fibrocell Science to Report Third Quarter 2014 Financial and Operating Results, and Host Conference Call and Webcast on November 7, 2014Printer Friendly Version
10/23/14Fibrocell Science Honored With 2014 Marcum Innovator of the Year AwardPrinter Friendly Version
10/03/14Fibrocell Science Announces Chief Financial Officer TransitionPrinter Friendly Version
09/30/14Fibrocell Science to Present at 2014 Stem Cell Meeting on the MesaPrinter Friendly Version
09/25/14Fibrocell Science to Present at BioCentury NewsMakers of the Biotech Industry ConferencePrinter Friendly Version
09/24/14Fibrocell Science and Intrexon Advance GM-HDF-COL7 toward Clinical Development for the Treatment of Recessive Dystrophic Epidermolysis BullosaPrinter Friendly Version
09/10/14Fibrocell Science Hosting R&D Day on September 24, 2014Printer Friendly Version
08/18/14Fibrocell Science, Inc. to Move Stock Listing to NASDAQPrinter Friendly Version
08/11/14Fibrocell Science Reports Second Quarter and First Half 2014 Financial and Operating ResultsPrinter Friendly Version
08/05/14Fibrocell Science to Present at Wedbush 2014 Life Sciences Management Access ConferencePrinter Friendly Version
08/04/14Fibrocell Science to Report Second Quarter 2014 Financial and Operating Results, and Host Conference Call and Webcast on August 11, 2014Printer Friendly Version
07/23/14Fibrocell Science Takes Active Role to Support Dystrophic Epidermolysis Bullosa Patient Advocacy GroupPrinter Friendly Version
06/17/14Fibrocell Science Announces Exclusive Technology License Agreements with UCLA to Advance the Development of Personalized Cell TherapiesPrinter Friendly Version
06/13/14Fibrocell Science Receives Orphan Drug Designation for Genetically-Modified Autologous Human Fibroblasts to Advance Treatment DevelopmentPrinter Friendly Version
06/02/14Fibrocell Science files Proxy Report on Form DEF-14A for the year ended December 31, 2013Printer Friendly Version
06/02/14Fibrocell Science files Annual Report on Form 10K/A for the year ended December 31, 2013Printer Friendly Version
05/29/14Fibrocell Science to Present at Jefferies 2014 Global Healthcare ConferencePrinter Friendly Version
05/28/14Fibrocell Science Announces Plans for Process Development and Manufacturing of Genetically-modified Cell Therapy for Rare Disease, RDEBPrinter Friendly Version
05/19/14Fibrocell Science Reports First Quarter 2014 Financial and Operating ResultsPrinter Friendly Version
05/16/14Fibrocell Science to Report First Quarter 2014 Financial and Operating Results, and Host Conference Call and Webcast on May 19, 2014Printer Friendly Version
05/12/14Fibrocell Science Announces Delay in Filing Quarterly Report on Form 10QPrinter Friendly Version
03/20/14Fibrocell Science to Present at 2nd Annual Regen Med Investor Day and BioCentury Future Leaders in the Biotech Industry ConferencePrinter Friendly Version
03/17/14Fibrocell Science Reports Fourth Quarter and Full Year 2013 Financial and Operating ResultsPrinter Friendly Version
03/10/14Fibrocell Science to Report Fourth Quarter and Full Year 2013 Financial and Operating Results, and Host Conference Call and Webcast on March 17Printer Friendly Version
03/05/14Fibrocell Science to Present at Barclays Global Healthcare Conference 2014Printer Friendly Version
01/13/14Fibrocell Science and Intrexon Expand Collaboration to Include Hypermobility-Type Ehlers-Danlos SyndromePrinter Friendly Version
01/06/14Fibrocell Science Appoints Robert Sheroff, Vice President of Technical OperationsPrinter Friendly Version
12/16/13Fibrocell Science Chairman & CEO David Pernock Joins BoardPrinter Friendly Version
11/14/13Fibrocell Science Announces Third Quarter 2013 Financial ResultsPrinter Friendly Version
10/25/13Fibrocell Science Honored with Partner in Progress Award from DEBRA of AmericaPrinter Friendly Version
10/07/13Fibrocell Science Announces Exercise of Over-AllotmentPrinter Friendly Version
10/03/13Fibrocell Science to Present at 2013 Stem Cell Meeting on the MesaPrinter Friendly Version
10/01/13Fibrocell Announces Completion of Public Offering of Common StockPrinter Friendly Version
09/26/13Fibrocell Science Prices Public Offering of Common StockPrinter Friendly Version
09/25/13Fibrocell Science Announces Proposed Public Offering of Common StockPrinter Friendly Version
09/04/13Fibrocell Science, Inc. to Present at Rodman & RenshawPrinter Friendly Version
08/26/13Fibrocell Science Appoints Greg Weaver Chief Financial Officer, Senior Vice President, Treasurer and Corporate SecretaryPrinter Friendly Version
08/19/13Fibrocell Science/UCLA Study on the Generation of Clinical Grade iPS Cells Yields Promising ResultsPrinter Friendly Version
07/02/13Fibrocell Science Extends Patent Protection for LAVIV® (azficel-T) Through 2031Printer Friendly Version
07/01/13Fibrocell Science and Intrexon Expand CollaborationPrinter Friendly Version
06/28/13Fibrocell Science Board of Directors Accepts Resignation of Chief Operating Officer and Chief Financial Officer Declan DalyPrinter Friendly Version
06/19/13Fibrocell Science to Join Russell IndexesPrinter Friendly Version
06/04/13Fibrocell Science CEO Rings the New York Stock Exchange Closing BellPrinter Friendly Version
05/15/13Fibrocell Science Announces Approval of Common Stock Listing on NYSE MKTPrinter Friendly Version
05/02/13Fibrocell Science Expands Potential Medical Applications for Azficel-TPrinter Friendly Version
04/29/13Fibrocell Science Announces One-for-Twenty-Five Reverse Stock SplitPrinter Friendly Version
04/26/13Fibrocell Science LAVIV® Recognized as 2013 Edison Awards’ Silver WinnerPrinter Friendly Version
04/24/13Fibrocell Science Pursues Premium Aesthetic Market Position for LAVIV®Printer Friendly Version
04/15/13Fibrocell Science Autologous Fibroblast Injections Show Improvement in Facial Acne Scar AppearancePrinter Friendly Version
04/02/13Fibrocell Science Reports 2012 ResultsPrinter Friendly Version
03/20/13Fibrocell/UCLA Study on Human Skin Cells Yields Promising ResultsPrinter Friendly Version
03/05/13Douglas J. Swirsky Joins Fibrocell BoardPrinter Friendly Version
02/21/13Fibrocell Adds New Member to its BoardPrinter Friendly Version
01/07/13Fibrocell Science, Inc. to Present at the 6th Annual OneMedForum San Francisco 2013Printer Friendly Version
12/17/12Fibrocell Science, Inc. to Initiate Phase II Clinical Trial for Restrictive Burn ScarsPrinter Friendly Version
10/25/12Fibrocell Science, Inc. Inducted into Prestigious World Technology NetworkPrinter Friendly Version
10/17/12Fibrocell Science, Inc. Receives Gold Award for LAVIV™ from Prestigious 2012 Golden Bridge Awards ProgramPrinter Friendly Version
10/16/12Fibrocell Science, Inc.’s LAVIV® Recognized in the Prestigious Wall Street Journal Technology Innovation AwardsPrinter Friendly Version
10/12/12Fibrocell Science, Inc. to Host Investor Conference Call to Discuss Business UpdatePrinter Friendly Version
10/08/12Fibrocell Science, Inc. Announces $45 Million Private Placement and Enters Strategic Collaboration with IntrexonPrinter Friendly Version
08/13/12Fibrocell Science, Inc. Announces Annual General MeetingPrinter Friendly Version
08/09/12Fibrocell Science, Inc. Announces Updated Investor PresentationPrinter Friendly Version
07/16/12Fibrocell Science, Inc. Completes $9.1 Million Capital RaisePrinter Friendly Version
07/16/12Fibrocell Science, Inc. Announces Second Quarter 2012 LAVIV Order InformationPrinter Friendly Version
06/08/12Fibrocell Science, Inc. Enters into Agreement to Sell Majority Ownership Stake in Agera Laboratories for $0.85 MillionPrinter Friendly Version
05/16/12Fibrocell Science, Inc. Announces Exclusive License Agreement with UCLA on Dermal Cell Research to Advance the Development of Personalized Cell TherapiesPrinter Friendly Version
05/15/12Fibrocell Science, Inc. and Top University Investigators Form Scientific Initiative to Assist in Securing Grant Funding for Research to Advance the Development of Personalized Cell TherapiesPrinter Friendly Version
05/14/12Fibrocell Science Submits a Phase II Study Protocol to the FDA To Evaluate the Use of azficel-T in Treating Restrictive Burn ScarsPrinter Friendly Version
05/03/12Fibrocell Science Technology Leads to Discovery of Two Rare Adult Stem Cell-Like Subpopulations in Human SkinPrinter Friendly Version
05/02/12Fibrocell Science, Inc. to Host Investor Conference Call to Discuss First Quarter 2012 Business UpdatePrinter Friendly Version
04/17/12LAVIV™ (azficel-T) Pivotal Trial Data Published in Peer-Reviewed Journal, Dermatologic SurgeryPrinter Friendly Version
04/02/12Fibrocell Science, Inc. Reschedules Fourth Quarter 2011 Business Update Investor Conference Call for Tuesday, April 3, at 8:00 AM Eastern TimePrinter Friendly Version
02/15/12Fibrocell Science, Inc. to Host Investor Conference Call to Discuss Fourth Quarter 2011 Business UpdatePrinter Friendly Version
01/30/12Fibrocell Science, Inc. Announces Recognition for LAVIVTM (azficel-T) at The 2012 Cell & Gene Therapy Forum, Washington, D.C.Printer Friendly Version
01/04/12Fibrocell Science, Inc. to Present at the 5th Annual OneMedForum San Francisco 2012Printer Friendly Version
12/01/11Fibrocell Science, Inc. to Present at the Oppenheimer 22nd Annual Healthcare ConferencePrinter Friendly Version
11/23/11Fibrocell Science, Inc. to Present at the Canaccord Genuity 6th Annual Cardiovascular, Aesthetics and Metabolic Disorders ConferencePrinter Friendly Version
11/08/11Fibrocell Science, Inc. to Host Investor Conference Call to Discuss Third Quarter 2011 Business UpdatePrinter Friendly Version
11/03/11LAVIV™ (azficel-T) Demonstrates Improvement in Acne ScarringPrinter Friendly Version
11/03/11Studies Show LAVIV™ (azficel-T) Effectively Improves the Appearance of Smile Line WrinklesPrinter Friendly Version
10/03/11Fibrocell Science, Inc. Announces Launch of LAVIV™ (azficel-T)Printer Friendly Version
09/28/11Fibrocell Science, Inc.’s LAVIV™ (azficel-T) Wins a 2011 Allure Best of Beauty AwardPrinter Friendly Version
09/16/11Fibrocell Science, Inc. Announces New Presentation Time at the UBS Global Life Sciences ConferencePrinter Friendly Version
09/15/11Fibrocell Science, Inc. to Present at the UBS Global Life Sciences ConferencePrinter Friendly Version
09/06/11Fibrocell Science, Inc. Announces New Presentation Time at the Kaufman Bros. 14th Annual Investor ConferencePrinter Friendly Version
08/30/11Fibrocell Science, Inc. to Present at the Rodman & Renshaw 13th Annual Healthcare ConferencePrinter Friendly Version
08/25/11Fibrocell Science, Inc. to Present at the Kaufman Bros. 14th Annual Investor ConferencePrinter Friendly Version
08/23/11Fibrocell Science, Inc. to Host Investor Conference Call to Discuss Business UpdatePrinter Friendly Version
08/22/11Fibrocell Science, Inc. to Raise $22.7 Million in Private PlacementPrinter Friendly Version
08/03/11Fibrocell Science, Inc. to Raise $22.7 Million in Private PlacementPrinter Friendly Version
06/22/11Fibrocell Science, Inc. Announces FDA Approval for LAVIV™ (azficel-T)Printer Friendly Version
03/10/11Fibrocell Science, Inc. to Present at the ROTH 23rd Annual OC Growth Stock ConferencePrinter Friendly Version
03/10/11Fibrocell Science, Inc. Submits Final Data from Histology Study to FDAPrinter Friendly Version
03/09/11Fibrocell Science, Inc. Accesses Patents from Stanford University on Fibroblast Research to Advance Cell TherapyPrinter Friendly Version
03/08/11Fibrocell Science, Inc. Announces Scientific Collaboration with UCLA on Fibroblast Research to Advance Cell TherapyPrinter Friendly Version
02/17/11Fibrocell Science, Inc. to Present at The Wall Street Analyst Forum 22nd Annual Analyst ConferencePrinter Friendly Version
02/16/11Fibrocell Science, Inc. Announces Positive Results of Its Pilot Study for Treatment of Vocal Fold Scarring With FibroblastsPrinter Friendly Version
02/15/11Fibrocell Science, Inc. Completes Capital RaisePrinter Friendly Version
01/12/11Fibrocell Science, Inc. Announces FDA Accepts for Review Complete Response Submission for Azficel-TPrinter Friendly Version
12/20/10Fibrocell Science, Inc. Submits Complete Response to FDA Regarding Azficel-TPrinter Friendly Version
11/17/10Fibrocell Science, Inc. Reports Third Quarter 2010 Financial Results and Provides Business UpdatePrinter Friendly Version
11/10/10Fibrocell Science, Inc. to Present at the Maxim Group Growth ConferencePrinter Friendly Version
11/03/10Fibrocell Science, Inc. Establishes Joint Venture to Market Its Technology Platform in AsiaPrinter Friendly Version
09/07/10Fibrocell Science, Inc. Names Biotechnology and Genetic Research Expert Stefan Gruenwald, M.D., Ph.D., to Scientific Advisory BoardPrinter Friendly Version
08/11/10Fibrocell Science, Inc. to Present at the 2010 Global Hunter Securities Healthcare ConferencePrinter Friendly Version
08/09/10Fibrocell Science, Inc. Submits CSR to U.S. Food and Drug Administration for Phase II/III Trial of Azficel-T in Acne ScarringPrinter Friendly Version
07/20/10Fibrocell Science, Inc. Announces Addition of Dr. George J. Korkos to Board of DirectorsPrinter Friendly Version
07/08/10Fibrocell Science, Inc. Completes Enrollment and First Treatment Visits for Histology Study of azficel-TPrinter Friendly Version
06/24/10Fibrocell Science, Inc. Appoints Advisors with Expertise in Periodontal/ Regenerative Dentistry and Burn CarePrinter Friendly Version
05/25/10The Irish Government and the Irish Voice Recognize Fibrocell Science, Inc.’s Declan Daly as “Irish Life Science 50” MemberPrinter Friendly Version
05/13/10Fibrocell Science, Inc. Initiates Histology Study of azficel-T (Study Data to Support BLA Complete Response)Printer Friendly Version
04/06/10Fibrocell Science, Inc. Announces Addition of Marc B. Mazur to Board of DirectorsPrinter Friendly Version
03/02/10Fibrocell Science, Inc. Enters Into Financing AgreementPrinter Friendly Version
02/02/10Fibrocell Science, Inc. Names David Pernock Chief Executive OfficerPrinter Friendly Version
12/21/09Fibrocell Science, Inc. Receives FDA Complete Response Letter Regarding azficel-T for WrinklesPrinter Friendly Version
10/09/09Fibrocell Science, Inc. Reports Outcome of FDA Advisory Committee Meeting on Azfibrocel-T for WrinklesPrinter Friendly Version
10/06/09Isolagen, Inc. Reorganizes as Fibrocell Science, Inc.Printer Friendly Version



Printer Friendly Version E-mail this page RSS E-mail Alerts Download Financial Tear Sheet